Evoke Pharma on Canadian patent for nasal spray

Evoke Pharma

06/07/2022 15:49

** Drug developer Evoke Pharma's shares  EVOK.O  rise 5.2%
to $3.23
    ** Co says it has received Canadian patent for Gimoti, its
nasal spray product to treat symptoms associated with diabetic
gastroparesis  urn:newsml:reuters.com:*:nGNX43JYMh
    ** Patent granted by Canadian Intellectual Property Office
covers methods of use for Gimoti and expires in 2029
    ** Diabetic gastroparesis is a disorder in which the stomach
takes too long to empty its contents, resulting in serious
gastrointestinal symptoms as well as other complications
    ** Stock down ~51.6% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))